Despite its utility, limitations of tau imaging include reports of in vivo off-target binding (Smith et al., 2022), variability of thresholds for tau positivity rates between studies (Weigand et al., 2022), and similarly as with amyloid, a positive tau marker alone is not sufficient for an AD diagnosis. Here, MAPT is linked to Alzheimer disease.